The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA

(2014) J.-B. Holz et al.   ANNALS OF THE RHEUMATIC DISEASES

Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics

(2014) Glynn Dennis et al.   ARTHRITIS RESEARCH & THERAPY

Interleukin 6 and Rheumatoid Arthritis

(2014) Yuji Yoshida et al.   Biomed Research International

Nanobodies: Natural Single-Domain Antibodies

(2013) Serge Muyldermans   Annual Review of Biochemistry

Nanobodies and their potential applications

(2013) Gholamreza Hassanzadeh-Ghassabeh et al.   Nanomedicine

PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis

(2013) Jacky Woo et al.   ARTHRITIS RESEARCH & THERAPY

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Current Understanding of Rheumatoid Arthritis Therapy

(2012) I Colmegna et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis

(2012) E. Choy   RHEUMATOLOGY

The pro- and anti-inflammatory properties of the cytokine interleukin-6

(2011) Jürgen Scheller et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis

(2011) Yoshikuni MIMATA et al.   International Journal of Rheumatic Diseases

XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

(2011) Alexander M. Owyang et al.   mAbs

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Neonatal Fc Receptor: From Immunity to Therapeutics

(2010) Timothy T. Kuo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis

(2010) Nicolas Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Unknown

(2010) Gianfranco Ferraccioli et al.   MOLECULAR MEDICINE

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab, a Humanized Anti-interleukin-6 Receptor Antibody, Ameliorates Joint Swelling in Established Monkey Collagen-Induced Arthritis

(2008) Yasushi Uchiyama et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

The significance of non-human primates as preclinical models of human arthritic disease

(2008) Michel Vierboom et al.   Expert Opinion on Drug Discovery